A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. But turning research into something that can improve patient outcomes and benefit healthcare ...

Astex Pharmaceuticals is set to make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics in Barcelona, Spain. The Astex presentations at the ...

CAMBRIDGE, United Kingdom, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small ...

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after disease progression on or after an EGFR-TKI.